Share This Author
Recent advances and perspectives of nucleic acid detection for coronavirus
Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond
The transcriptional regulation of P450 genes by two major xenobiotic nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), and the polymorphisms of PXR and CAR are discussed.
Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system.
Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells.
Absorption and excretion of luteolin and apigenin in rats after oral administration of Chrysanthemum morifolium extract.
- Ting Chen, Li-ping Li, Xin-yan Lu, Huidi Jiang, S. Zeng
- Chemistry, MedicineJournal of Agricultural and Food Chemistry
- 24 January 2007
The study of the absorption and excretion of luteolin and apigenin in rats after a single oral dose of CME suggests apigen in may be absorbed more efficiently than luteolin in CME in rats, and both lutenolin and Apigenin have a slow elimination phase, with a quick absorption, so a possible accumulation of the two flavonoids in the body can be hypothesized.
Involvement of P‐glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin
The results indicated that Ginkgo flavonols quercetin, kaempferol and isorhamnetin were substrates of P‐ gp, and the P‐gp type efflux pump might limit the bioavailability of Gink Go flavonol.
Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9.
Studies on oral absorption of stearic acid SLN by a novel fluorometric method.
PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA.
Role of Catechol-O-Methyltransferase in the Disposition of Luteolin in Rats
- Zhong-jian Chen, Meng Chen, Huidi Jiang
- Biology, ChemistryDrug Metabolism and Disposition
- 1 April 2011
The results indicated that the methylation pathway in rats was significantly reduced when luteolin was coadministered with a specific COMT inhibitor, and COMT-associated drug-drug interactions need be considered in the future in lutingolin clinical trials because the plasma concentrations and related therapeutic effects may be altered in vivo in the presence of a COMT inhibitors.